- Meeting abstract
Platelets and platelet-activating factor acetylhydrolase in septic patients
Critical Care volume 3, Article number: P086 (2000)
Platelet-activating factor (PAF) and its inactivating enzyme PAF-acetyl-hydrolase (PAF-AH) are implicated in the development of sepsis and its sequela septic shock. It has been shown that the administration of r PAF-AH has a beneficial effect on the outcome of sepsis in animals as well as in humans.
We measured PAF-AH activity daily in 2586 plasma samples that were obtained from 240 patients admitted to our intensive care unit. Patients were screened daily for sepsis according to ACCP/SCCM criteria, and PAF-AH activities were analysed in relation to severity of sepsis and to whole blood platelet count as an indicator of platelet activation and consumption.
PAF-AH activity was positively correlated to the severity of disease, but was proved to be a poor sepsis marker, when compared to others, such as neopterin, TNFα, procalcitonin etc. In patients with septic shock a low PAF-AH activity (<2.00 μmol/ml/h) could indicate a high mortality risk. Only 4 patients met these criteria, but all died. Platelet count was highest in patients with uncomplicated sepsis, but dropped dramatically in septic shock. The overall correlation between PAF-AH and platelet count was relatively poor (r = 0.266), but remarkable differences were observed between patients with PAF-AH activities <2.001 or >5.00) μmol/ml/h, resp.: 125 (70/112) × 108/ml versus 280 (206/388) × 108/ml; P < 0.00l.
Our data provide further evidence that PAF-AH has a beneficial effect in sepsis and that it can prevent platelet activation and sequestration which is known to contribute to multiple organ failure.
About this article
Cite this article
Ruβwurm, S., Dohrn, B., Oberhoffer, M. et al. Platelets and platelet-activating factor acetylhydrolase in septic patients. Crit Care 3 (Suppl 1), P086 (2000). https://doi.org/10.1186/cc460